Monday, September 20, 2021 4:13:07 PM
Zacks Equity Research
Mon, September 20, 2021, 11:40 AM
ZTS
+0.14%
COLL
-1.01%
Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Collegium Pharmaceutical and Zoetis are sporting Zacks Ranks of #1 (Strong Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that COLL has an improving earnings outlook. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
COLL currently has a forward P/E ratio of 5.31, while ZTS has a forward P/E of 43.84. We also note that COLL has a PEG ratio of 0.27. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ZTS currently has a PEG ratio of 3.17.
Another notable valuation metric for COLL is its P/B ratio of 2.76. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ZTS has a P/B of 21.62.
Based on these metrics and many more, COLL holds a Value grade of A, while ZTS has a Value grade of C.
COLL stands above ZTS thanks to its solid earnings outlook, and based on these valuation figures, we also feel that COLL is the superior value option right now.
https://finance.yahoo.com/news/coll-vs-zts-stock-value-154003011.html
Recent COLL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 08:32:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 02:39:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 02:06:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 09:52:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/06/2024 03:53:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 08:47:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 12:03:46 PM
- Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2024 12:00:00 PM
- Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/15/2024 08:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 06:41:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 08:34:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:04:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:01:35 PM
- Collegium Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 10:02:38 AM
- Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology • GlobeNewswire Inc. • 07/29/2024 10:00:00 AM
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:05:25 PM
- Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise • GlobeNewswire Inc. • 06/13/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 08:50:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:06:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:36:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 09:22:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 05:59:12 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM